During the past decade, Pusat Darah Negara conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Pusat Darah Negara" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Pusat Darah Negara" are "Hemophilia A" (2 trials). Many other conditions were trialed in "Pusat Darah Negara" in a lesser frequency.

Most popular intervention types in "Pusat Darah Negara" are "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method" (1 trials), "BAX855" (1 trials) and "PEGylated Recombinant Factor VIII" (1 trials). Other intervention names were less common.

The vast majority of trials in "Pusat Darah Negara" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Pusat Darah Negara". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Pusat Darah Negara, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Pusat Darah Negara, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".